ISTANBUL, May 26, 2011 /PRNewswire/ — Arena Pharmaceuticals,
Inc. (NASDAQ:
ARNA) today presented meta-analyses of the three trials in the
lorcaserin Phase 3 clinical trial program at ECO 2011, the 18th
European Congress on Obesity. The analyses show that lorcaserin
caused statistically significant weight loss compared to placebo at
one year among 7,500 obese and overweight, diabetic and
non-diabetic adults. The lorcaserin-mediated weight loss was
associated with favorable changes in biomarkers that may be
predictive of cardiovascular and metabolic risk and in quality of
life.
Christen M. Anderson, M.D., Ph.D., Arena’s Vice President,
Lorcaserin Development, stated, “We are pleased to have the
opportunity to share and discuss the results from the lorcaserin
Phase 3 program with the European medical community at ECO, and we
look forward to submitting a Marketing Authorization Application
for regulatory approval of lorcaserin in Europe next year.”
At one year, using Modified Intent-to-Treat with Last
Observation Carried Forward analysis (MITT-LOCF) of the integrated
results, 46.3% of lorcaserin 10 mg twice daily (BID) patients and
40.6% of lorcaserin 10 mg once daily (QD) patients achieved at
least 5% weight loss, compared to 22.1% of patients on placebo, and
22.0% of lorcaserin 10 mg BID patients and 17.3% of lorcaserin 10
mg QD patients achieved at least 10% weight loss, compared to 8.3%
of patients on placebo. Of the patients completing year one of the
trials, 62.3% of lorcaserin 10 mg BID patients and 52.8% of
lorcaserin 10 mg QD patients achieved at least 5% weight loss,
compared to 32.0% of patients on placebo, and 33.5% of lorcaserin
10 mg BID patients and 25.5% of lorcaserin 10 mg QD patients
achieved at least 10% weight loss, compared to 13.8% of patients on
placebo. Notably, this meta-analysis included approximately 600
patients enrolled with type 2 diabetes, a
‘/>”/>
SOURCE